跳至主要内容
临床试验/NCT05088928
NCT05088928Unknown2 期

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical

Scotmann Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
40
试验地点
1
主要终点
Bleeding

研究概览

简要总结

The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.

详细描述

There is an increased risk of Venous and Arterial thromboembolism in COVID-19 infection. The main reason being that the novel coronavirus SARS-CoV-2 induces hyperinflammation and subsequently immunothrombolism which is wide spread in the body. The angiotensin converting enzyme 2 (ACE2) receptor, which is utilized by the virus to infect the host, is present throughout the human body organs and endothelial cells. Thrombotic microangiopathies are the consequence of this direct endothelial invasion of the virus and widespread endothelial inflammation. Consequently, pervasive dysfunction of the endothelium and apoptosis is seen primarily due to the host immune response and release of pro inflammatory cytokines.

A hypercoagulable state is therefore seen due to the shift in the vascular equilibrium towards a vasoconstrictive and inflammatory response, promoting a microvascular derangement and dysfunctions.

Although this pathological response is not unique to the COVID-19 disease, the systemic coagulopathies observed due to this novel virus are noted to be slightly distinct. These include the increased risk of mortality with the increased level of D-Dimers in nearly 50% of the patients . While mild prolongation of Prothrombin time and thrombocytopenia are not noted to be important predictors of the severity of the disease or its adverse outcomes .

In COVID-19 patients, the International Society on Thrombosis and Hemostasis (ISTH). criteria for Disseminated Intravascular Coagulation (DIC) is seldom met, despite the indication by the typical triad of thrombin time prolonged, decreased platelet counts and increased D-dimer levels .

Although the Disseminated Intravascular Coagulation is low grade, the fibrinolytic system is activated and endogenous tissue plasminogen is released because of the pathogenic inflammation-causing endothelial cell injury and thrombotic angiopathies of the microvascular system. This also contributes to the increased mortalities due to high D-Dimer levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (≥18 years of age)
  • All admitted patients with severe or critical COVID-19
  • Confirmed diagnosis of COVID-19 through RT-PCR (attach report) and/or HRCT Chest
  • Patients at high risk of coagulopathy demonstrating signs of micro-thrombi induced organ dysfunction or strongly suspected macro thromboembolism

排除标准

  • High risk of bleeding as judged by treating physicians
  • Contra-indication to therapeutic anti coagulation
  • Platelets < 50,000 (attach report)
  • INR >1.5
  • Evidence of current or recent bleeding

研究组 & 干预措施

Interventional Arm

Experimental

Ecru (Apixaban )Tablets

干预措施: Apixaban (Drug)

Comparator/control

Active Comparator

Rivascot (Rivaroxaban)

干预措施: Rivaroxaban (Drug)

结局指标

主要结局

Bleeding

时间窗: 10 days

The participants with bleeding episodes

次要结局

  • Clotting(10 days)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Dr. Syeda Saba Aslam

Head of Medical Affairs

Scotmann Pharmaceuticals

研究点 (1)

Loading locations...

相似试验